Ionis' TRYNGOLZA Nears EU Approval for Severe Hypertriglyceridemia

  • CHMP recommends EU approval for TRYNGOLZA (olezarsen) in severe hypertriglyceridemia (sHTG) ahead of schedule.
  • Final European Commission decision expected in Q4 2026.
  • Phase 3 CORE and CORE2 studies showed 72% triglyceride reduction and 85% fewer pancreatitis events vs. placebo.
  • Ionis and Sobi aim to expand TRYNGOLZA's EU market beyond its current approval for familial chylomicronemia syndrome (FCS).

Ionis' TRYNGOLZA represents a novel RNA-targeted approach to severe hypertriglyceridemia, a condition affecting ~2 million EU patients with triglyceride levels ≥880 mg/dL. The CHMP's accelerated recommendation underscores the unmet need for therapies that reduce acute pancreatitis risk in this high-risk population. If approved, TRYNGOLZA would become the first RNA-targeted treatment for sHTG in the EU, expanding Ionis' footprint beyond its existing FCS indication.

Regulatory Timing
Whether the European Commission will finalize approval by year-end 2026 as projected.
Commercial Execution
How Ionis and Sobi will position TRYNGOLZA against existing sHTG treatments in the EU.
Pipeline Leverage
The pace at which Ionis can replicate this success with other RNA-targeted therapies.